FORM OF SUBSCRIPTION AGREEMENTSubscription Agreement • October 13th, 2021 • Rezolute, Inc. • Pharmaceutical preparations • California
AFTER THE EXECUTION OF THIS AGREEMENT BY THE INVESTOR AND THE COMPANY, THE INVESTOR SHALL AT CLOSING REMIT BY WIRE TRANSFER THE AMOUNT OF FUNDS EQUAL TO THE AGGREGATE PURCHASE PRICE FOR THE SECURITIES BEING PURCHASED BY THE INVESTOR TO THE FOLLOWING ACCOUNT:
6,030,847 Shares of Common Stock Pre-Funded Warrants to Purchase 1,661,461 Shares of Common Stock Rezolute, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 13th, 2021 • Rezolute, Inc. • Pharmaceutical preparations • New York
Rezolute, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of 6,030,847 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and pre-funded warrants (the “Warrants”) to purchase up to 1,661,461 shares of Common Stock in lieu thereof at an exercise price of $0.01 per share in the form attached hereto as Exhibit A. The respective amounts of the Firm Shares and Warrants to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 1,153,845 shares (the “Company Option Shares”) of Common Stock from the Company for the purpose of covering over-allotment
